For more than two decades, strong evidence has indicated variation in the quality of cancer care in the United States.[@CR1]--[@CR19] As a result, measurements and audits are necessary to search for gaps in the quality of care. Toward this end, multiple professional organizations have developed condition-specific quality measures (QMs) to assess the clinical performance surrounding the patient-provider encounter.

Quantification of performance can identify variation and opportunities for improvement. If performance assessment is followed by performance comparison among peers (i.e., benchmarking) coupled with transparency among providers, physicians who find themselves in the lower tiers of performance can be motivated to improve, ultimately yielding better overall care at the population level, a phenomenon that recently has been reviewed and demonstrated by several programs.[@CR20]--[@CR26]

This report aims to describe how the American Society of Breast Surgeons (ASBrS) ranked and defined measures of quality of care and subsequently provided benchmarking functionality for its members to compare their performances with each other. By separate investigations, the actual performance demonstrated by our ASBrS membership for compliance with nine breast surgeon-specific QMs are reported.

Founded in 1995, the ASBrS is a young organization. Yet, within 20 years, membership has grown to more than 3000 members from more than 50 countries. A decade ago, the Mastery of Breast Surgery Program (referred to as "Mastery" in this report) was created as a patient registry to collect quality measurement data for its members.[@CR27]

Past President Eric Whitacre, who actually programmed Mastery's original electronic patient registry with his son Thomas, understood that "quality measures, in their mature form, did not merely serve as a yardstick of performance, but were a mechanism to help improve quality."[@CR28],[@CR29] Armed with this understanding, the ASBrS integrated benchmarking functionality into Mastery, thus aligning the organization with the contemporary principles of optimizing cancer care quality as described by policy stakeholders.[@CR2],[@CR19],[@CR25],[@CR30]

In 2010, Mastery was accepted as a Center for Medicaid and Medicare Services (CMS) Physicians Qualified Reporting Service (PQRS) and then as a Qualified Clinical Data Registry (QCDR) in 2014, linking provider performance to government reimbursement and public reporting.[@CR31] Surgeons who successfully participated in Mastery in 2016 will avoid the 2018 CMS "payment adjustment" (2% penalty), a further step toward incentivizing performance improvement in tangible ways.

Methods {#Sec1}
=======

Institutional Review Board {#Sec2}
--------------------------

De-identified QM data were obtained with permission from the ASBrS for the years 2011--2015. The Institutional Review Board (IRB) of the Gundersen Health System deemed the study was not human subjects' research. The need for IRB approval was waived.

Choosing, Defining, and Vetting QM {#Sec3}
----------------------------------

From 2009 to 2016, the Patient Safety and Quality Committee (PSQC) of the ASBrS solicited QM domains from its members and reviewed those of other professional organizations.[@CR32]--[@CR39] As a result, as early as 2010, a list of more than 100 domains of quality had been collected, covering all the categories of the Donabedian trilogy (structure, process, and outcomes) and the National Quality Strategy (safety, effectiveness, efficiency, population health, care communication/coordination, patient-centered experience).[@CR40],[@CR41] By 2013, a list of 144 measures underwent three rounds of modified Delphi process ranking by eight members of the PSQC, using a RAND/UCLA Appropriateness Methodology, which replicated an American College of Surgeons effort to rank melanoma measures and was consistent with the National Quality Forum's guide to QM development[@CR42],[@CR43] (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). During the ranking, quality domains were assigned a score of 1 (not valid) to 9 (valid), with a score of 5 denoting uncertain/equivocal validity. After each round of ranking, the results were discussed within the PSQC by email and phone conferences. At this time, arguments were presented for and against a QM and its rank. A QM was deemed valid if 90% of the rankings were in the range of seven to nine.Table 1Instructions of the American Society of Breast Surgeons for ranking of quality measure domains*Ranking* [@CR42],[@CR43]1. \[Evaluate the quality domains\] for appropriateness (median ranking) and agreement (dispersion of rankings) to generate quality indicators2. A measure \[will be\] considered valid if adherence with this measure is critical to provide quality care to patients with \[breast cancer\], regardless of cost or feasibility of implementation. Not providing the level of care addressed in the measure would be considered a breach in practice and an indication of unacceptable care3. Validity rankings are based on the panelists' own personal judgments and not on what they thought other experts believed4. The measures should apply to the average patient who presents to the average physician at an average hospital*Importance criteria* [@CR57]1. Variation of care2. Feasibility of measurement, without undue burden3. Usability for accountability \[public transparency or quality payment programs\]4. Applicability for quality improvement activity*Scoring criteria* [@CR42],[@CR43]1 = not valid5 = uncertain/equivocal validity9 = validVerbatim instructions from an American College of Surgeons ranking study[@CR43] Table 2Hierarchy of quality domains for breast surgeons after the 3rd round of modified Delphi rankingQuality domainMedian score^a^Validity^b^Agreement^c^*Patients receiving diagnosis of cancer by needle biopsy*9YesAgreementPatients undergoing a formal patient-side-site-procedure verification procedure in the operating room9NoAgreement*Percentage of cancer patients with orientation of lumpectomy specimen*9YesAgreement*Clinical stages 1 and 2 node-negative patients offered sentinel lymph node (SLN) surgery*9YesAgreementMastectomy patients with ≥4 positive nodes referred to radiation oncologist9YesAgreementStages 1, 2, and 3 patients undergoing initial breast cancer surgery with documentation of ER, PR receptor status9NoAgreementStage 1, 2, and 3 undergoing initial breast cancer surgery with documentation of HER2 neu status9NoAgreementBreast conservation therapy (BCT) patients referred to radiation oncology9YesAgreementPercentage of patients undergoing neoadjuvant therapy before planned breast conservation surgery (BCS) who have imaging marker clip placed in breast9YesAgreement*Percentage of patients undergoing lumpectomy for non-palpable cancer with specimen imaging performed*9YesAgreementPatients with concordance assessment (testing) of Exam-Imaging-Path by care provider9NoAgreementPatients undergoing breast cancer surgery with final path report indicating largest single tumor size8.5NoAgreementPatient's compliant with National Quality Forum Quality Measures (NQF QM) for endocrine therapy in hormonal receptor positive patients8.5YesAgreementTrastuzumab is considered or administered within 4 months (120 days) after diagnosis for stage 1, 2, or 3 breast cancer that is HER2-positive8.5NoAgreementDocumentation of mastectomy patients offered referral to plastic surgery8.5YesAgreementDocumentation of eligibility of BCT and eligible patients offered BCT8.5YesAgreementPatients with documentation of patient options for treatment regardless of procedure type8.5YesAgreementPercentage of patients undergoing BCT with a final ink-negative margin, regardless of number of operations8.5NoAgreementPatients with adequate history by care provider8NoAgreementPatients with documentation of postoperative cancer staging (AJCC)8YesAgreementPatient's compliant with NQF QM for radiation after lumpectomy8NoAgreementPatients with documentation preoperative (pretreatment) AJCC clinical staging8YesAgreementNCCN compliance with radiation guidelines8NoAgreementMastectomy patients receiving preoperative antibiotics8YesAgreementPatients with NCCN guideline compliant care for "high risk lesions" identified on needle biopsy (ADH, ALH, FEA, LCIS, papillary lesion, radial scar, mucin-containing lesion)8NoAgreementPatients with NCCN guidelines compliant care for diagnostic evaluation of breast lump8NoAgreementPatients with NCCN compliance for postoperative lab imaging, biomarkers in stages 0, 1, and 2 patients8NoAgreementNCCN guideline compliance for genetic testing among patients with newly diagnosed breast cancer8NoAgreementNCCN guideline compliance for genetics assessment/referral among patients with newly diagnosed breast cancer8NoAgreementPatients with adequate examination by care provider7.5NoAgreementPatients with final pathologic size ≥ stage 1 T1cN0M0 who have documentation of discussion regarding adjuvant treatment7.5YesAgreementDocumentation of reason why patient is not eligible for BCT7.5NoIndeterminantPatients with adequate review of imagining by care provider7.5NoIndeterminantPatients with inflammatory or locally advanced breast cancer who undergo neoadjuvant treatment before surgery7.5NoAgreementHigh-risk patients with estimated lifetime risk \>20% offered screening MRI7.5NoIndeterminantNCCN compliance for medical oncology recommendations7.5NoIndeterminantRisk adjusted re-excision lumpectomy rate after breast-conserving therapy7.5YesAgreementNCCN guideline compliance for inflammatory breast cancer7.5NoIndeterminantNCCN guideline compliance for breast cancer in pregnancy7.5NoIndeterminantPatients with predicted estimate of BRCA mutation \>10% offered BRCA testing7.5NoIndeterminantHigh-risk patients (no known cancer) with documentation of risk-reduction counseling7.5NoIndeterminantNCCN guideline compliance for inadequate margins requiring re-excision in BCS patients7.5NoAgreementPatients receiving antibiotics within 1 h before surgery7YesAgreement*Patients receiving a first- or second-generation cephalosporin before incision*7YesAgreement*Patients with discontinuations of antibiotics within 24 h after surgery*7YesAgreementPatients with Surgical Care Improvement Project (SCIP) antibiotic measure compliance (includes all 3 measures above)7YesAgreement*Patients with breast cancer with documentation of risk assessment for germline mutation*7NoIndeterminantPatients compliant with SCIP DVT/PE prophylaxis recommendations7NoIndeterminantPatients ≤50 years with newly diagnosed breast cancer offered genetic testing7YesAgreementPatients presented to interdisciplinary tumor board (real or virtual) at any time7NoAgreementPatients compliant with NQF QM for chemotherapy in hormonal receptor-negative patients7NoIndeterminantSurgical-site infection rate (mastectomy patients)7NoIndeterminantPercentage of patients entered into a patient registry to identify patient complications and cancer outcomes7NoIndeterminant*One-step surgery success rate stratified by type of operation (mastectomy)*7NoIndeterminantSentinel lymph node identification rate (%) in breast cancer surgery7YesAgreementCosmetic score (measure of cosmesis) after BCS (patient self-assessment with Harvard score)7NoIndeterminantTime (business days) from diagnostic evaluation to needle biopsy7NoIndeterminantTime (business days) from needle biopsy path report to surgical appointment7NoIndeterminantSurgical-site infection rate (mastectomy plus plastic surgery patients)7NoIndeterminantIpsilateral breast tumor recurrence (IBTR)7NoIndeterminantPercentage of patients undergoing lumpectomy for non-palpable cancer with two-view specimen imaging performed7NoIndeterminantPercentage of compliance with ASBrS or ACR annotation of ultrasound (US) images7NoIndeterminantPercentage of compliance with ASBrS or ACR recommendations for US reports7NoIndeterminantPercentage of compliance with ASBrS or ACR recommendations for US needle biopsy reports7NoIndeterminantCompliance with ASBrS or ACR recommendations for US needle biopsy reports7NoIndeterminantNCCN guideline compliance for pre-op lab and imaging in clinical stages 0, 1, and 2 patients with cancer7NoIndeterminantPatients with preoperative needle biopsy proven axillary node who do not undergo sentinel node procedure7NoIndeterminantLocal regional recurrence7NoIndeterminantPatients age ≥70 years, hormone receptor positive, with invasive cancer offered endocrine therapy instead of radiation (documentation)7NoIndeterminantDisease-free survival6.5NoIndeterminantTime business days from new breast cancer to office appointment6.5NoIndeterminantPatients with predicted estimate of BRCA mutation \>10% who are tested6.5NoIndeterminantTime business days from needle biopsy path report of cancer to surgical operation6.5NoIndeterminantTime business days from abnormal screening mammography to diagnostic evaluation6.5NoIndeterminantPercentage of cancer patients entered into a quality audit (any type: institutional, personal case log, regional, national)6.5NoIndeterminantTime business days from new breast symptom to office appointment6.5NoIndeterminantPatients with benign breast disease with documentation of risk assessment for cancer6.5NoIndeterminantPercentage of patients with partial breast irradiation after lumpectomy who are compliant with "ASBrS guidelines for eligibility"6.5NoIndeterminantPercentage of patients with partial breast irradiation after lumpectomy who are compliant with "ASTRO guidelines for eligibility"6.5NoIndeterminantNumber of breast-specific CMEs per year6.5NoIndeterminantNCCN compliance for SLN surgery in stage 0 DCIS6.5NoIndeterminantSkin flap necrosis rate after mastectomy stratified by type of mastectomy reconstruction, type of reconstruction6.5NoIndeterminantOverall survival6NoIndeterminantRatio of malignant-to-benign minimally invasive breast biopsies6NoIndeterminant*Surgical-site infection rate (all patients)*6NoIndeterminantSurgeon US (2 × 2 test table performance) (sensitivity, specificity, PPV, NPV) for surgeons performing diagnostic breast evaluation with imaging6NoIndeterminantNCCN guideline compliance for phyllodes tumor6NoIndeterminantCompliance with ASBrS or ACR recommendations for stereotactic biopsy reports6NoIndeterminantTime business days from surgeon appointment for cancer to surgery for cancer6NoIndeterminantPercentage of mastectomy patients undergoing reconstruction6NoIndeterminantCost of perioperative episode of care (affordability)6NoAgreementPatients with cancer diagnosed for core needle biopsy (CNB) for BiRads 4a lesion6NoIndeterminantPatients with cancer diagnosed for CNB for BiRads 4b lesion6NoIndeterminantPatients with cancer diagnosed for CNB for BiRads 4c lesion6NoIndeterminantPatients with cancer diagnosed for CNB for BiRads 5 lesion6NoIndeterminantNCCN guideline compliance for Paget's disease6NoIndeterminantSurgical-site infection rate (BCS patients)6NoIndeterminantNumber of axillary nodes obtained in patients undergoing level 1 or 2 nodal surgery (median)6NoIndeterminantPercentage of DCIS patients undergoing BCS for cancer who do not have axillary surgery6NoIndeterminantPatients with College of American Pathologists (CAP) compliant reporting5.5NoIndeterminantBreast cancer patients presented to interdisciplinary tumor board (real or virtual) before 1st treatment5.5NoIndeterminantPercentage of cancer patients enrolled in clinical trials5.5NoIndeterminantMastectomy patients with positive SLN who undergo completion of axillary dissection5.5NoIndeterminantPatients with cancer diagnosed on CNB for BiRads 3 lesion5.5NoIndeterminantPatients with unifocal cancer smaller than 3 cm who undergo BCT5.5NoIndeterminantPatients with documentation of pre-op breast size and symmetry5.5NoIndeterminantClinical stage 0 DCIS patients who do not undergo SLN surgery for BCT5.5NoIndeterminantPatients undergoing level 1 or 2 axillary dissection with ≥15 nodes removed5.5NoIndeterminantNumber of SLN's (median) in patients undergoing SLN procedure5.5NoIndeterminantBreast volume (number of cancer cases per year per surgeon)5.5NoIndeterminantPercentage of cancer patients with documentation of search for clinical trial5.5NoIndeterminantPercentage of breast biopsy pathology requisition forms containing adequate information for pathologist (history, CBE, imaging)5NoAgreementTime from initial cancer surgery to pathology report5NoIndeterminantPatients with documentation of pre-op contralateral breast cancer risk5NoIndeterminantClinical stage 0 DCIS patients who do not undergo SLN surgery for mastectomy5NoIndeterminantBCT rate (actual and potential)5NoIndeterminantTime business days from abnormal screening mammogram (SM) to office appointment5NoIndeterminantPatients with documentation of needle biopsy results delivered to patients within 48 h5NoIndeterminantBCT-eligible patients offered neoadjuvant treatment5NoAgreementInterval cancers (cancer detected within 1 year after negative US biopsy or stereotactic biopsy)5NoIndeterminantCosmetic score (measure of cosmesis) after mastectomy, no reconstruction (patient self-assessment)5NoIndeterminantPercentage of cancer patients referred to medical oncology5NoIndeterminantAxillary recurrence rate5NoIndeterminantPatients with NCCN guidelines compliant care for nipple discharge5NoDisagreementPercentage of BCT patients with marker clips placed in lumpectomy cavity to aid radiation oncologist for location of boost dose for radiation5NoIndeterminantPercentage of patients with documentation of arm edema status post-operatively4.5NoIndeterminantPatients undergoing re-operation within 30 days (stratified by case type)4.5NoIndeterminantPatients undergoing re-admission within 30 days (stratified by base type)4.5NoIndeterminantPercentage of BCT patients with oncoplastic procedure performed4.5NoIndeterminantPatients with documentation of gynecologic/sexual side effects of endocrine therapy4.5NoIndeterminantPatients with documentation of gynecologic/sexual changes during follow-up4.5NoIndeterminantMastectomy patients who undergo immediate intraoperative SLN assessment4.5NoIndeterminantPatients with latragenic injury to adjacent organ, structure (stratified by case type)4NoIndeterminantPercentage of lumpectomy patients with surgeon use of US intraoperatively4NoIndeterminantPatients with documentation of surgical pathology results delivered to patients within 96 h4NoIndeterminantPatients who have "grouped" postoperative appointments (same day, same location with care providers)4NoIndeterminantPercutaneous procedure complications3.5NoIndeterminantPercentage of patients with development of lymphedema of arm after axillary surgery3.5NoIndeterminantTime from initial cancer surgery to pathology report3NoDisagreementPatients with new DVT less than or equal to 30 days post-operatively3NoDisagreementPatients with new PE ≤30 days post-operatively3NoIndeterminantDocumentation of use of new NSQIP-generated ACS risk calculator preoperatively3NoIndeterminantPatients with unplanned overnight stay stratified by procedure type2.5NoIndeterminantSensitivity of immediate intraoperative detection of positive SLN (pathology quality measure)2.5NoAgreementPatients with myocardial infarction ≤30 days postoperatively2NoAgreementPatients with new renal failure ≤30 days postoperatively2NoAgreementPatients with new respiratory failure ≤30 days post-operatively2NoAgreement*ER* estrogen receptor; *PR* progesterone receptor; *HER2* human epidermal growth factor 2; *AJCC* American Joint Committee on Cancer; *NCCN* National Comprehensive Cancer Network; *ADH* Atypical Ductal Hyperplasia; *ALH* Atypical lobular hyperplasia; *FEA* Flat epithelial atypia; *LCIS* Lobular carcinoma in situ; *MRI* magnetic resonance imaging; *SCIP* Surgical care improvment project; *DVT* Deep venous thrombosis; *PE* Pulmonary embolism; *ASBrS* American Society of Breast Surgeons; *ACR* American College of Radiology; *ASTRO* American Society of therapuetic radiation oncologists; *CME* Continuing medical education credits; *DCIS* Ductal carcinoma in situ; *PPV* positive predictive value; *NPV* negative predictive value; *CBE* clinical breast exam; *NSQIP* National Surgical Quality Improvement Program; *ACS* American Cancer Society^a^Median score 1--9: lowest to highest^b^Validity: ≥90% of the rankings are in the 7--9 range^c^Agreement: Based on scoring dispersion (e.g., for a panel of 13, there is "agreement" if \>8 rankings are in any 3-point range and disagreement if \>3 rankings are 1--3 and 7--9Italicized text: Final ASBrS QM chosen for CMS quality payment programs

After three rounds of ranking ending in December 2013, nine of the highest ranked measures were "specified" as described and required by CMS[@CR44] (Table [3](#Tab3){ref-type="table"}). Briefly, exclusions to QM reporting were never included in the performance numerator or denominator. Exceptions were episodes in which performance for a given QM was not met but there was a justifiable reason why that was the case. If so, then the encounter, similar to an exclusion, was not included in the surgeon's performance rate. If an encounter met performance criteria despite typically meeting exception criteria, the encounter was included in the performance rate. Per CMS rules, each QM was linked to a National Quality Strategy Aim and Domain (Table [3](#Tab3){ref-type="table"}). The QMs also were assigned to a Donabedian category and to one or more of the Institute for Healthcare Improvement's "triple aims."[@CR40],[@CR45] Table 3American Society of Breast Surgeons Quality Measure Specifications for participation in the Center for Medicaid and Medicare Services Qualified Clinical Data Registry[@CR55],[@CR56]QM titleQM nameQM numeratorQM denominatorException examples^a^Exclusion examples^b^Measure type^c^NQS domain(s)^d^IHI triple aim^e^Needle biopsyPQRS measure \#263: Preoperative diagnosis of breast cancerNo. of patients age ≥18 years undergoing breast cancer operations who had breast cancer diagnosed preoperatively by a minimally invasive biopsyNo. of patients age ≥18 years on date of encounter undergoing breast cancer operationsLesion too close to implant\
Patient too obese for stereotactic table\
Contralateral prophylactic mastectomy\
Needle performed but identified "high risk" lesion onlyNot a breast procedureProcessEffective clinical care\
Efficiency and cost reductionCare experience\
Per capita costImage confirmationPQRS measure \#262: Image confirmation of successful excision of image-localized breast lesionPatient undergoing excisional biopsy or partial mastectomy of a nonpalpable lesion whose excised breast tissue was evaluated by imaging intraoperatively to confirm successful inclusion of targeted lesionNo. of patients age ≥18 years on date of encounter with nonpalpable, image-detected breast lesion requiring localization of lesion for targeted resectionTarget lesion identified intraoperatively by pathology\
MRI wire localization for lesion occult on mammography and ultrasoundLesion palpable preoperatively\
Re-excision surgery for margins\
Ductal excision without visible lesion on imagingProcessPatient safetyCare experienceSentinel nodePQRS measure \#264: Sentinel lymph node biopsy for invasive breast cancerPatients who undergo a sentinel lymph node biopsy procedurePatients age ≥18 years with clinically node-negative stage 1 or 2 primary invasive breast cancerPrior nodal surgery\
Recurrent cancer\
Limited life expectancyNo preoperative invasive cancer diagnosis\
Patient has proven axillary metastasis\
Inflammatory breast cancerProcessEffective clinical care\
SafetyCare experience\
Per capita costHereditary assessmentASBS 1: Surgeon assessment for hereditary cause of breast cancerNo. of breast cancer patients with newly diagnosed invasive and DCIS seen by surgeon who undergo risk assessment for a hereditary cause of breast cancerNo.of newly diagnosed invasive and DCIS breast cancer patients seen by surgeon and who undergo surgeryPatient was adopted\
Family history not obtainable for any specific reasonLCIS patients\
Patient does not have breast cancer or patient does not undergo surgeryProcessEffective clinical care\
Community and population health (e.g., screening for germline mutation in family members)Care experience\
Population healthSurgical-site infectionASBS 2: Surgical-site infection and cellulitis after breast and/or axillary surgeryNo. of patients age ≥18 years who experience an SSI or cellulitis within 30 days after undergoing a breast and/or an axillary operationNo. of patients age ≥18 years on date of encounter undergoing a breast and/or axillary operationNonePatient did not undergo breast or axillary surgeryOutcomePerson and caregiver-centered experience and outcomesCare experience\
Per capita costSpecimen orientationASBS 3: Specimen orientation for partial mastectomy or excisional breast biopsyNo. of patients age ≥18 years undergoing a therapeutic breast surgical procedure considered an initial partial mastectomy or "lumpectomy" for a diagnosed cancer or an excisional biopsy for a lesion that is not clearly benign based on previous biopsy or clinical and radiographic criteria with surgical specimens properly oriented for pathologic analysis such that six margins can be identifiedNo. of patients age ≥18 years undergoing a therapeutic breast surgical procedure considered an initial partial mastectomy or "lumpectomy" for a diagnosis of cancer or an excisional biopsy for a lesion that is not clearly benign based on previous biopsy or clinical and radiographic criteriaClinical and imaging findings suggest benign lesion (e.g., fibroadenoma)Patients who had total mastectomy (all types)ProcessCommunication and care coordinationCare experienceAntibiotic choiceASBS 5: Perioperative care: Selection of prophylactic antibiotics: first- or second-generation cephalosporin (modified for breast from PQRS measure \#21)Surgical patients age ≥18 years undergoing procedures with indications for a first- or second- generation cephalosporin prophylactic antibiotic who had an order for a first- or second -generation cephalosporin for antimicrobial prophylaxisAll surgical patients age ≥18 years undergoing procedures with the indications for a first- or second -generation cephalosporin prophylactic antibioticPatient allergic to cephalosporinsNot a breast procedureProcessPatient safetyCare experience\
Per capita costAntibiotic durationASBS 6: Perioperative care: Discontinuation of prophylactic parenteral antibiotics (modified for breast from PQRS measure \#22)Noncardiac surgical patients who have an order for discontinuation of prophylactic parenteral antibiotics within 24 h after surgical end timeAll noncardiac surgical patients age ≥18 years undergoing procedures with the indications for prophylactic parenteral antibiotics and who received a prophylactic parenteral antibioticAntibiotic *not* discontinued: ordered by plastic surgeon for expander or implant insertionNot a breast procedureProcessPatient safetyCare experience\
Per capita costMastectomy reoperationUnplanned 30-day re-operation rate after mastectomyPatients undergoing mastectomy who do not require an unplanned secondary breast or axillary operation within 30 days after the initial procedurePatients undergoing uni- or bilateral mastectomy as their initial proscedure for breast cancer or prophylaxis.Patients who have a contralateral breast reoperation attributed to plastic surgeon for a complication in a breast not operated on by the breast surgeon\
Patients with autologous flap necrosis attributed to plastic surgeonPatient underwent lumpectomy as his or her initial operationOutcomePatient safety\
Efficiency and cost reductionCare experience\
Per capita costSpecifications[@CR55],[@CR56]*QM* quality measure; *NQS* National Quality Strategy; *IHI* Institute for Healthcare Improvement; *PQRS* Physicians Quality Reporting Service; *MRI* magnetic resonance imaging; *ASBS* American Society of Breast Surgeons; *LCIS* Lobular carcinoma in situ; *DCIS* ductal carcinoma in situ; *SSI* surgical site infection^a^Exceptions mean the patient encounter is included only in the numerator and denominator if "performance was met."^b^Exclusions mean the patient encounter is never included in the numerator or denominator^c^Donabedian domain[@CR40]^d^National Quality Strategy domain[@CR41]^e^Institute for Healthcare Improvement Triple Aim[@CR45]

Each of our QMs underwent vetting in our electronic patient registry (Mastery) by a workgroup before submission to CMS. During this surveillance, a QM was modified, retired, or advanced to the QCDR program based on member input and ASBrS Executive Committee decisions.

Patient Encounters {#Sec4}
------------------

To calculate the total number of provider-patient-measure encounters captured in Mastery, we summed the total reports for each individual QM for all study years and all providers who entered data.

Benchmarking {#Sec5}
------------

Each surgeon who entered data into Mastery was able to compare his or her up-to-date performance with the aggregate performance of all other participating surgeons (Fig. [1](#Fig1){ref-type="fig"}). The surgeons were not able to access the performance metrics of any other named surgeon or facility.Fig. 1Example of real-time peer performance comparison after surgeon entry of quality measures

Data Validation {#Sec6}
---------------

In compliance with CMS rules, a data validation strategy was performed annually. A blinded random selection of at least 3% of QCDR surgeon participants was conducted. After surgeons were selected for review, the ASBrS requested that they send the ASBrS electronic and/or paper records to verify that their office/hospital records supported the performance "met" and "not met" categories that they had previously reported to the ASBrS via the Mastery registry.

Results {#Sec7}
=======

Hierarchical Order and CMS QCDR Choices {#Sec8}
---------------------------------------

The median ranking scores for 144 potential QMs ranged from 2 to 9 (Table [2](#Tab2){ref-type="table"}). The nine QMs chosen and their ranking scores were appropriate use of preoperative needle biopsy (9.0), sentinel node surgery (9.0), specimen imaging (9.0), specimen orientation (9.0), hereditary assessment (7.0), mastectomy reoperation rate (7.0), preoperative antibiotics (7.0), antibiotic duration (7.0), and surgical-site infection (SSI) (6.0). The specifications for these QMs are presented in Table [3](#Tab3){ref-type="table"}. The mastectomy reoperation rate and SSI are outcome measures, whereas the remainder are process of care measures.

QM Encounters Captured {#Sec9}
----------------------

A total of 1,286,011 unique provider-patient-measure encounters were captured in Mastery during 2011--2015 for the nine QCDR QMs. Performance metrics and trends for each QM are reported separately.

Data Validation {#Sec10}
---------------

The QM reporting rate of inaccuracy by surgeons participating in the 2016 QCDR data validation study of the 2015 Mastery data files was 0.82% (27 errors in 3285 audited patient-measure encounters). Subsequent reconciliation of discordance between surgeon QM reporting and patient clinical data occurred by communication between the ASBrS and the reporting provider.

CMS Acceptance and Public Transparency {#Sec11}
--------------------------------------

The Center for Medicare and Medicaid Services accepted the ASBrS QM submitted to them for PQRS participation in 2010--2013 and for QCDR in 2014--2016. In 2016, they discontinued the specimen orientation measure for future reporting and recommended further review of the mastectomy reoperation rate measure. Public reporting of 2015 individual surgeon QCDR data was posted in 2016 on the ASBrS website.

Security {#Sec12}
--------

To our knowledge, no breaches have occurred with any surgeon-user of Mastery identifying the performance of any other surgeon or the identity of any other surgeon's patients. In addition, no breaches by external sources have occurred within the site or during transmission of data to CMS.

Discussion {#Sec13}
==========

Modified Delphi Ranking of QM {#Sec14}
-----------------------------

To provide relevant QM for our members, the PSQC of the ASBrS completed a hierarchal ranking of more than 100 candidate measures and narrowed the collection of QMs to fewer than a dozen using accepted methods.[@CR42],[@CR43] Although not reported here, the same process was used annually to identify new candidate QMs from 2014 to 2017 for future quality payment programs and to develop measures for the Choosing Wisely campaign.[@CR46] Based on our experience, we recommend its use for others wanting to prioritize longer lists of potential QM domains into shorter lists. These lists are iterative, allowing potential measures to be added anytime, such as after the publication of clinical trials or after new evidence-based guidelines are developed for better care. In addition, with the modified Delphi ranking process, decisions are made by groups, not individuals.

After Ranking, What Next? {#Sec15}
-------------------------

Of the nine QMs selected for submission to CMS, only four had the highest possible ranking score. The reasons for not selecting some highly ranked domains of care included but were not limited to the following concerns. Some QMs were already being used by other organizations or were best assessed at the institutional, not the surgeon, level, such as the use of radiation after mastectomy for node-positive patients.[@CR32]--[@CR36] Other highly ranked measures, such as "adequate history," were not selected because they were considered standard of care.

Contralateral prophylactic mastectomy rates, a contemporary topic of much interest, was not included in our original ranking, and breast-conserving therapy (BCT) was not ranked high due to our concern that both were more a reflection of patient preferences and of regional and cultural norms than of surgeon quality. A lumpectomy reoperation QM was ranked high (7.5), but was not chosen due to disagreement within the ASBrS whether to brand this a quality measure.[@CR47],[@CR48] In some cases, QMs with lower scores were selected for use for specific reasons. For example, by CMS rules, two QMs for a QCDR must be "outcome" measures, but all our highest ranked measures were "process of care" measures.

There was occasional overlap between our QM and those of other organizations.[@CR21],[@CR32]--[@CR39] In these cases, we aimed to harmonize, not compete with existing measures. For example, a patient with an unplanned reoperation after mastectomy would be classified similarly in both the National Surgical Quality Improvement Program (NSQIP) and our program. In contrast to NSQIP, we classified a patient with postoperative cellulitis as having an SSI. Because excluding cellulitis as an SSI event has been estimated to reduce breast SSI rates threefold, adoption of the NSQIP definition would underestimate the SSI burden to breast patients and could limit improvement initiatives.[@CR49]

Governance {#Sec16}
----------

Ranking and specifying QMs is arduous. Consensus is possible; unanimous agreement is rare. Therefore, a governance structure is necessary to reconcile differences of opinion. In our society, the PSQC solicits, ranks, and specifies QMs. A workgroup vets them for clarity and workability. In doing so, the workgroup may recommend changes. The ASBrS Executive Committee reconciles disputes and makes final decisions .

Reporting Volume {#Sec17}
----------------

Our measurement program was successful, capturing more than 1 million provider-patient-measure encounters. On the other hand, our member participation rate was less than 20%. By member survey (not reported here), the most common reason for not participating was "burden of reporting."

Benchmarking {#Sec18}
------------

"Benchmarking" is a term used most often as a synonym for peer comparison, and many programs purport to provide it.[@CR25] In actuality, benchmarking is a method for improving quality and one of nine levers endorsed by the National Quality Strategy to upgrade performance.[@CR21],[@CR23],[@CR30],[@CR50] Believing in this concept, the ASBrS and many other professional societies built patient registries that provided benchmarking.[@CR21],[@CR25],[@CR32]--[@CR35] In contradistinction, the term "benchmark" refers to a point of reference for comparison. Thus, a performance benchmark can have many different meanings, ranging from a minimal quality threshold to a standard for superlative performance.[@CR24],[@CR36]

Program strengths {#Sec19}
=================

Our patient registry was designed to collect specialty-specific QMs as an alternative to adopting existing general surgical and cross-cutting measures. Cross-cutting measures, such as those that audit medicine reconciliation or care coordination, are important but do not advance specialty-specific practice. Furthermore, breast-specific measures lessen potential bias in the comparison of providers who have variable proportions of their practice devoted to the breast. Because alimentary tract, vascular, and trauma operations tend to have higher morbidity and mortality event rates than breast operations, general surgeons performing many non-breast operations are not penalized in our program for a case mix that includes these higher-risk patients. In other words, nonspecialized general surgeons who want to demonstrate their expertise in breast surgery can do so by peer comparison with surgeons who have similar case types in our program. In addition, a condition-specific program with public transparency allows patients to make more informed choices regarding their destination for care. In 2016, individual provider report-carding for our participating surgeons began on the "physician-compare" website.[@CR51]

Another strength of an organ-specific registry is that it affords an opportunity for quick Plan-Do-Study-Act (PDSA) cycles because personal and aggregate performance are updated continuously. Thus action plans can be driven by subspecialty-specific data, not limited to expert opinion or claims data. For example, a national consensus conference was convened, in part, due to an interrogation of our registry that identified wide variability of ASBrS member surgeon reoperation rates after lumpectomy.[@CR52],[@CR53] Other program strengths are listed in Table [4](#Tab4){ref-type="table"}.Table 4Strengths and limitations of the American Society of Breast Surgeons quality measurement program*Strengths*Specialty measures and their specifications developed by surgeonsJustifiable "exceptions" to not meeting performance defined by surgeonsReal-time surgeon data entry lessens recall bias, abstractor error, and misclassification of attribution for not meeting a performance requirementReal-time peer performance comparisonLarge sample size of patient-measure encounters (\>1,000,000) for comparisonsGeneral surgeons able to compare breast surgical performance to breast-specialty surgeonsLow level of erroneous reporting based on auditsParticipation satisfies American Board of Surgery Maintenance of Certification Part 4Public transparency of individual surgeon performance in 2015 on the American Society of Breast Surgeons (ASBrS) website in 2016Capability to use the program for "plan-do-study-act" cycles[@CR52],[@CR53]No participation fee for members before 2016^a^*Limitations*Peer performance comparison not yet risk-adjustedUnknown rate of nonconsecutive patient data entryNo significant patient or payer input into quality measure list or ranking to reflect their preferences and values[@CR54]Unknown rate of surgeon "dropout" due to their perception of poor performance^a^\$100.00 began 2016

Study Limitations {#Sec20}
=================

Although risk-adjusted peer comparisons are planned, to date, we are not providing them. In addition, only the surgeons who participate with CMS through our QCDR sign an "attestation" statement that they will enter "consecutive patients," and no current method is available for cross-checking the Mastery case log with facility case logs for completeness. Recognizing that nonconsecutive case entry (by non-QCDR surgeons) could alter surgeon performance rates, falsely elevating them, one investigation of Mastery compared the performance of a single quality indicator between QCDR- and non--QCDR-participating surgeons.[@CR52] Performance did not differ, but this analysis has not been performed for any of the QMs described in this report. Surgeons also can elect to opt out of reporting QMs at any time. The percentage of surgeons who do so due to their perception of comparatively poor performance is unknown. If significant, this self-selected removal from the aggregate data would confound overall performance assessment, falsely elevating it.

Another limitation is our development of QMs by surgeons with minimal patient input and no payer input. As a result, we cannot rule out that these other stakeholders may have a perception of the quality of care delivered to them that differs from our perception. For example, patients might rank timeliness of care higher than we did, and payers of care might rank reoperations the highest, given its association with cost of care. We may not even be measuring some domains of care that are most important to patients because we did not uniformly query their values and preferences upfront during program development, as recommended by others.[@CR2],[@CR54] See Table [4](#Tab4){ref-type="table"} for other limitations.

Conclusion {#Sec21}
==========

In summary, the ASBrS built a patient registry to audit condition-specific measures of breast surgical quality and subsequently provided peer comparison at the individual provider level, hoping to improve national performance. In 2016, we provided public transparency of the 2015 performance reported by our surgeon participants.[@CR55],[@CR56] In doing so, we have become stewards, not bystanders, accepting the responsibility to improve patient care. We successfully captured more than 1 million patient-measure encounters, participated in CMS programs designed to link reimbursement to performance, and provided our surgeons with a method for satisfying American Board of Surgery Maintenance of Certification requirements. As public and private payers of care introduce new incentivized reimbursement programs, we are well prepared to participate with our "tested" breast-specific QMs.
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